Novel Mechanistic Insights into Arginine Deiminase Pharmacology Suggest <sup>18</sup>F-FDG Is Not Suitable to Evaluate Clinical Response in Melanoma
Lars Stelter(Memorial Sloan Kettering Cancer Center), Steven M. Larson(Memorial Sloan Kettering Cancer Center)
Cited by 18
Related Papers
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
|The Lancet|2010|1.1k
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
|New England Journal of Medicine|2013|825
Long-Term Prognostic Significance of Extent of Rectal Cancer Response to Preoperative Radiation and Chemotherapy
|Annals of Surgery|2002|284
Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2013|264
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
|European Journal of Nuclear Medicine and Molecular Imaging|2013|182